Rhodes-Lyons Heather X, McClure David L, Hill Kalli, Schultz Tiana, Brandl Gina, Roberts Jennifer, Martinek Lucy, Pepe Antonio
Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.
Department of Surgery, Division of Graduate Medical Education, Marshfield Clinic Health System, Marshfield, WI, USA.
Am Surg. 2025 Jul;91(7):1170-1177. doi: 10.1177/00031348251329469. Epub 2025 Apr 10.
BackgroundThe clinical decision to administer venous thromboembolism prophylaxis (VTE PPX) is determined by an assumption of low rebleeding risk. Findings from this study will inform clinical decisions designed to help traumatic brain injury (TBI) patients avoid VTE complications.MethodsThis retrospective cohort study utilized the ACS-TQIP-PUF from 2017 to 2021. The study population consisted of adult (≥15 years) patients who received LMWH, UFH, or mechanical filter VTE PPX with no missing times and had a blunt isolated TBI. The population was split into two groups, patients with and without a comorbid history of anticoagulation or bleeding disorder (BLEED). The Modified Berne-Norwood Criteria (mBNC) was applied to distinguish each group based on size and TBI type into a low, moderate, and high risk of rebleeding.ResultsA total of 99,078 patients were included in the analysis; 75,952 (76.6%) did not have a comorbid BLEED. A protective effect against mortality, DVT and PE if VTE PPX was given very early in both the low- and moderate-risk groups (all values < .01). The high-risk group found a higher likelihood of mortality in the very early and mid VTE PPX BLEED group (all values ≤ .03).ConclusionVery early (≤24 hr) VTE PPX in the low- and moderate-risk mBNC reports to be effective in preventing VTE and mortality. Very early VTE PPX in the high-risk group prevents VTE; however, it is associated with a higher likelihood of mortality in BLEED groups.
静脉血栓栓塞预防(VTE PPX)的临床决策取决于再出血风险较低的假设。本研究结果将为旨在帮助创伤性脑损伤(TBI)患者避免VTE并发症的临床决策提供依据。
这项回顾性队列研究使用了2017年至2021年的ACS-TQIP-PUF。研究人群包括接受低分子肝素、普通肝素或机械滤器VTE PPX且无时间缺失的成年(≥15岁)钝性孤立性TBI患者。人群分为两组,有和没有抗凝或出血性疾病(BLEED)合并病史的患者。应用改良的伯尔尼-诺伍德标准(mBNC)根据大小和TBI类型将每组分为再出血低、中、高风险组。
共有99078例患者纳入分析;75952例(76.6%)没有合并BLEED。在低风险和中风险组中,如果非常早期给予VTE PPX,对死亡率、深静脉血栓形成(DVT)和肺栓塞(PE)有保护作用(所有值<0.01)。高风险组发现,在VTE PPX的非常早期和中期,BLEED组的死亡可能性更高(所有值≤0.03)。
在低风险和中风险mBNC中,非常早期(≤24小时)的VTE PPX报告显示对预防VTE和死亡率有效。高风险组的非常早期VTE PPX可预防VTE;然而,在BLEED组中,它与更高的死亡可能性相关。